EMCC 2011: MEDIAN to present a poster
MEDIAN Technologies (ALMDT), the leading provider of clinical applications for quantitative management of treatment responses in oncology imaging, announces its participation to the EMCC 2011 to be held September 23-27, in Sweden. For this occasion, the company will present the results of a study on the lesion volume used in the evaluation of the treatment response of patients with advanced non-small cell lung cancer.
This presentation (poster 1147) is on schedule for the « Translational Research » session on the 24th of September 2011 from 9:30 a.m. to noon. It is entitled « Inter-reader Agreement in Response to Therapy Evaluation of Advanced Lung Cancer: Benefits of a Volume-derived Imaging Biomarker ». The abstract is available on the internet: http://stockholm2011.ecco-org.eu/
The study is based on follow-up CT scans of 10 patients affected by advanced non-small cell lung cancer. This study shows the impact of the use of MEDIAN LMS clinical applications on the inter-reader variability decrease for the evaluation of the treatment response according to RECIST criteria: the study shows both the advantages of the lesion volume measurement and advanced reviewing tools offered by LMS.
« We are very proud of this study’s results » underlines Arnaud Butzbach, Chief Technology Officer and Vice-President Operations at MEDIAN. « They correspond to an additional step in demonstrating the interest of advanced imaging biomarkers in oncology, and are completely along the lines of MEDIAN Technologies project: provide pharmaceutical companies and physicians with powerful image-based data for a more reliable evaluation of the response to therapy in cancer patients ».
MEDIAN LMS clinical applications as well as MEDIAN CTIS (Clinical Trial Imaging Services), the offer dedicated to clinical trials, will be presented on MEDIAN booth C13:13 during the whole conference
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”